by Dennis Crouch
Welcome to August 2024. This post offers a recap of some of the week’s events.
Democrat VP Nominee Gov. Tim Walz apparently owns no stocks. For those of us that do, this week experienced extremely high price volatility. One of the biggest losers of the week (percentage wise) is Houston based FibroBiologics, Inc. (Nasdaq: FBLG) whose 3rd quarter Q-10 reported “substantial doubt about our ability to continue as a going concern.” The filing noted increased R&D costs, delay in clinical trials for their wound healing fibroblast treatments, and financing struggles. The companies 150+ issued/pending patents (global) and are likely the company’s largest assets. Currently pending APN 17/757,309 includes what seems to be a very broad claim of administering fibrobrasts to treat or prevent kidney disease:
1. A method of preventing or treating kidney disease in an individual having, or at risk of having, kidney disease comprising administering a prophylactically or therapeutically effective amount of fibroblasts, modified fibroblasts, and/or products derived from fibroblasts.
The examiner has not yet passed judgment on the claim. Melissa Sistrunk at Norton Rose appears to be handling the prosecution. (more…)